An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

Trial Profile

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs M 4344 (Primary) ; Carboplatin; Cisplatin; Gemcitabine
  • Indications Ovarian cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors EMD Serono Research & Development Institute; Vertex Pharmaceuticals
  • Most Recent Events

    • 25 May 2018 Planned End Date changed from 27 May 2019 to 27 Sep 2019.
    • 25 May 2018 Planned primary completion date changed from 27 May 2019 to 23 Sep 2019.
    • 25 May 2018 Part A2 consisting "M4344 BID or once daily" is added to the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top